Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2518041 | 0.98 | HPGD (0.39) | ALDH1A1ATMHPGDPTGS1PDE4A | |
| SCHEMBL2492273 | 0.98 | HPGD (0.39) | ALDH1A1ATMHPGDPTGS1PDE4A | |
| SCHEMBL6584519 | 0.98 | ALDH1A1 (0.36) | ALDH1A1ATMHPGDPTGS1PDE4A | |
| SCHEMBL9320849 | 0.95 | PTGS1 (0.36) | ALDH1A1ATMHPGDPTGS1PDE4A | |
| SCHEMBL8078390 | 0.90 | — | — | |
| SCHEMBL6114858 | 0.86 | CYP1A2 (0.43) | ALDH1A1ATMHPGDCYP1A2SIGMAR1 | |
| SCHEMBL4896518 | 0.84 | CYP1A2 (0.46) | HPGDCYP1A2METAP1SIGMAR1EPHX1 | |
| SCHEMBL355314 | 0.82 | SIGMAR1 (0.47) | CYP1A2SIGMAR1EPHX1APP | |
| Ammonia Solution, Strong SCHEMBL8491678 | 0.82 | CYP1A2 (0.45) | HPGDCYP1A2METAP1SIGMAR1EPHX1 | |
| SCHEMBL8322595 | 0.82 | SIGMAR1 (0.47) | CYP1A2SIGMAR1EPHX1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511219-B | Phenyl-substituted dihydronaphthyridine compound and application thereof | 年衍药业(珠海)有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3063231-A1 | ACID DYES, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE | DyStar Colours Distribution GmbH (DE) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015062939-A1 | ACID DYES, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE | DYSTAR COLOURS DISTRIBUTION GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| EP-2024361-A1 | 3-TETRAZOLYL INDAZOLES, 3-TETRAZOLYL PYRAZOLOPYRIDINES, AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| US-7452908-B2 | Amide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-11-18 | — | — | US | disclosed |
| WO-2007128454-A1 | 3-TETRAZOLYL INDAZOLES, 3-TETRAZOLYL PYRAZOLOPYRIDINES, AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-11-15 | — | — | WO | disclosed |
| US-6809108-B1 | SELECTIVE MUSCARINIC M3 RECEPTOR ANTAGONTS; REDUCED SIDE EFFECTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20040204369-A1 | Novel amide derivatives | MSD K.K. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1213281-B1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-5308830-A | Low dosage; nonphytotoxic to crops; pre- and postemergence | ROHM AND HAAS COMPANY (US) | 1994-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204369-A1 | Novel amide derivatives | CHRM3, CHRM1, CHRM2 | ALDH1A1 1744/4885ATM 1425/4885HPGD 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.